CA2959943C - Liquid inhalation formulation comprising rpl554 - Google Patents

Liquid inhalation formulation comprising rpl554 Download PDF

Info

Publication number
CA2959943C
CA2959943C CA2959943A CA2959943A CA2959943C CA 2959943 C CA2959943 C CA 2959943C CA 2959943 A CA2959943 A CA 2959943A CA 2959943 A CA2959943 A CA 2959943A CA 2959943 C CA2959943 C CA 2959943C
Authority
CA
Canada
Prior art keywords
rpl554
composition according
liquid
concentration
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2959943A
Other languages
English (en)
French (fr)
Other versions
CA2959943A1 (en
Inventor
Peter Lionel Spargo
Edward James FRENCH
Phillip A. Haywood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1416274.7A external-priority patent/GB201416274D0/en
Priority claimed from GBGB1504662.6A external-priority patent/GB201504662D0/en
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Publication of CA2959943A1 publication Critical patent/CA2959943A1/en
Application granted granted Critical
Publication of CA2959943C publication Critical patent/CA2959943C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2959943A 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554 Active CA2959943C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1416274.7 2014-09-15
GBGB1416274.7A GB201416274D0 (en) 2014-09-15 2014-09-15 Formulation
GB1504662.6 2015-03-19
GBGB1504662.6A GB201504662D0 (en) 2015-03-19 2015-03-19 Formulation
PCT/GB2015/052668 WO2016042313A1 (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554

Publications (2)

Publication Number Publication Date
CA2959943A1 CA2959943A1 (en) 2016-03-24
CA2959943C true CA2959943C (en) 2022-08-16

Family

ID=54196992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2959943A Active CA2959943C (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554

Country Status (27)

Country Link
US (2) US9956171B2 (cg-RX-API-DMAC7.html)
EP (3) EP3332767B1 (cg-RX-API-DMAC7.html)
JP (2) JP6860477B2 (cg-RX-API-DMAC7.html)
KR (1) KR102379309B1 (cg-RX-API-DMAC7.html)
CN (3) CN106794157B (cg-RX-API-DMAC7.html)
AU (3) AU2015316592B2 (cg-RX-API-DMAC7.html)
CA (1) CA2959943C (cg-RX-API-DMAC7.html)
CY (3) CY1120264T1 (cg-RX-API-DMAC7.html)
DK (3) DK3494962T3 (cg-RX-API-DMAC7.html)
ES (3) ES2875584T3 (cg-RX-API-DMAC7.html)
HK (1) HK1249415B (cg-RX-API-DMAC7.html)
HR (3) HRP20180833T1 (cg-RX-API-DMAC7.html)
HU (3) HUE055527T2 (cg-RX-API-DMAC7.html)
IL (1) IL250895B (cg-RX-API-DMAC7.html)
LT (3) LT3332767T (cg-RX-API-DMAC7.html)
MX (1) MX2017003102A (cg-RX-API-DMAC7.html)
MY (1) MY196072A (cg-RX-API-DMAC7.html)
NO (1) NO3193835T3 (cg-RX-API-DMAC7.html)
PH (1) PH12017500479B1 (cg-RX-API-DMAC7.html)
PL (3) PL3332767T3 (cg-RX-API-DMAC7.html)
PT (3) PT3494962T (cg-RX-API-DMAC7.html)
RS (3) RS57227B1 (cg-RX-API-DMAC7.html)
RU (1) RU2699995C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201701854WA (cg-RX-API-DMAC7.html)
SI (3) SI3494962T1 (cg-RX-API-DMAC7.html)
SM (3) SMT201800242T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016042313A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2688191C2 (ru) 2014-05-12 2019-05-21 ВЕРОНА ФАРМА ПиэЛСи Новое лечение
MY196072A (en) * 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
JP6814754B2 (ja) 2015-07-24 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂａｃｅ１阻害剤ペプチド
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
AU2021208129A1 (en) * 2020-01-15 2022-08-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition of tricyclic PDE3/PDE4 dual inhibitor compound
GB202002786D0 (en) * 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN119816295A (zh) * 2022-08-08 2025-04-11 维罗纳制药公司 液体药物组合物
CA3263546A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Plc ENSIFENTRINE (RPL-554) FOR THE TREATMENT OF MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
WO2024088364A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种包含异喹啉酮类化合物的药物组合物及其制备方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
TW202506117A (zh) 2023-06-26 2025-02-16 英商維羅納製藥Ｐｌｃ公司 顆粒組成物
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
WO2025052119A1 (en) * 2023-09-06 2025-03-13 Verona Pharma Plc Ensifentrine for use in treating chronic obstructive pulmonary disease (copd)
US20250249006A1 (en) * 2024-02-05 2025-08-07 Verona Pharma Plc Treatment
US20250249008A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
US20250249007A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
ES2172217T3 (es) * 1997-10-09 2002-09-16 Schering Corp Suspensiones de furoato de mometasona para nebulizacion.
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
DK1165558T3 (da) 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0122031D0 (en) 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
RU2440972C2 (ru) * 2004-12-17 2012-01-27 Сипла Лимитед Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
RU2580835C2 (ru) * 2010-06-22 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Алкалоидные производные на основе сложных аминоэфиров и композиции лекарственных средств, содержащие их
TWI516488B (zh) * 2010-08-09 2016-01-11 維羅納製藥Ｐｌｃ公司 嘧啶并［６，１－ａ］異喹啉－４－酮化合物之結晶型
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2717855A4 (en) * 2011-06-07 2014-11-12 Parion Sciences Inc PROCESSING METHODS
EP2647627A1 (en) * 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
WO2014037727A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Carcainium salts
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
WO2015137720A1 (ko) * 2014-03-11 2015-09-17 엘지전자 주식회사 무선 통신 시스템에서 장치 대 장치 단말의 디스커버리 신호 전송 방법 및 장치
RU2688191C2 (ru) 2014-05-12 2019-05-21 ВЕРОНА ФАРМА ПиэЛСи Новое лечение
MY196072A (en) * 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
NZ767296A (en) 2024-01-26
SI3193835T1 (en) 2018-06-29
PH12017500479A1 (en) 2017-07-31
SI3332767T1 (sl) 2019-07-31
ES2875584T3 (es) 2021-11-10
PH12017500479B1 (en) 2021-07-21
CN111249260B (zh) 2023-01-10
CN106794157B (zh) 2021-03-09
CA2959943A1 (en) 2016-03-24
HUE055527T2 (hu) 2021-12-28
JP6795574B2 (ja) 2020-12-02
EP3494962B1 (en) 2021-05-26
NZ729796A (en) 2024-01-26
JP2019069978A (ja) 2019-05-09
RU2017108432A (ru) 2018-10-17
JP6860477B2 (ja) 2021-04-14
LT3494962T (lt) 2021-07-26
HUE038433T2 (hu) 2018-10-29
EP3193835A1 (en) 2017-07-26
HRP20191122T1 (hr) 2019-09-20
AU2020203081A1 (en) 2020-05-28
ES2730810T3 (es) 2019-11-12
RU2017108432A3 (cg-RX-API-DMAC7.html) 2019-04-01
SMT201900340T1 (it) 2019-07-11
CN111249260A (zh) 2020-06-09
HRP20211035T1 (hr) 2021-09-17
MY196072A (en) 2023-03-13
PT3193835T (pt) 2018-03-27
WO2016042313A1 (en) 2016-03-24
CY1120264T1 (el) 2019-07-10
HRP20180833T1 (hr) 2018-06-29
SG11201701854WA (en) 2017-04-27
LT3332767T (lt) 2019-06-25
AU2018286571B2 (en) 2020-04-02
BR112017005050A2 (pt) 2018-01-23
NO3193835T3 (cg-RX-API-DMAC7.html) 2018-08-04
KR20170054406A (ko) 2017-05-17
MX2017003102A (es) 2017-06-14
PL3332767T3 (pl) 2019-10-31
LT3193835T (lt) 2018-06-11
AU2015316592A1 (en) 2017-03-23
AU2020203081B2 (en) 2021-08-05
KR102379309B1 (ko) 2022-03-28
RS62252B1 (sr) 2021-09-30
US20170239178A1 (en) 2017-08-24
US10945950B2 (en) 2021-03-16
PL3193835T3 (pl) 2018-07-31
HUE045303T2 (hu) 2019-12-30
IL250895B (en) 2019-08-29
SI3494962T1 (sl) 2021-09-30
SMT201800242T1 (it) 2018-07-17
CY1121698T1 (el) 2020-07-31
CN110051627A (zh) 2019-07-26
NZ767295A (en) 2024-01-26
AU2018286571A1 (en) 2019-01-24
DK3494962T3 (da) 2021-06-21
SMT202100479T1 (it) 2021-09-14
PT3332767T (pt) 2019-06-27
CY1124546T1 (el) 2022-07-22
CN106794157A (zh) 2017-05-31
AU2015316592B2 (en) 2020-04-02
PT3494962T (pt) 2021-06-22
RS58897B1 (sr) 2019-08-30
EP3193835B1 (en) 2018-03-07
JP2017528479A (ja) 2017-09-28
EP3332767B1 (en) 2019-03-20
ES2670025T3 (es) 2018-05-29
PL3494962T3 (pl) 2021-12-06
HK1249415B (en) 2019-11-22
DK3332767T3 (da) 2019-06-24
US20180369139A1 (en) 2018-12-27
RU2699995C2 (ru) 2019-09-12
EP3494962A1 (en) 2019-06-12
IL250895A0 (en) 2017-04-30
RS57227B1 (sr) 2018-07-31
DK3193835T3 (en) 2018-05-07
EP3332767A1 (en) 2018-06-13
US9956171B2 (en) 2018-05-01

Similar Documents

Publication Publication Date Title
AU2020203081B2 (en) Liquid inhalation formulation comprising RPL554
HK1249415A1 (en) Liquid inhalation formulation comprising rpl554
ES2970571T3 (es) Composición farmacéutica líquida que comprende ensifentrina y glicopirrolato
US20240041805A1 (en) Pharmaceutical compositions of niclosamide and a protein
HK40007474A (en) Liquid inhalation formulation comprising rpl554
HK40007474B (en) Liquid inhalation formulation comprising rpl554
WO2022007743A1 (zh) 粘膜给药剂型和其应用
HK1233919B (en) Liquid inhalation formulation comprising rpl554
HK1233919A1 (en) Liquid inhalation formulation comprising rpl554
BR112017005050B1 (pt) Composições farmacêuticas líquidas, nebulizador e usos da composição farmacêutica líquida

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200728

EEER Examination request

Effective date: 20200728

EEER Examination request

Effective date: 20200728